Results 61 to 70 of about 43,946 (263)

Population pharmacokinetic modelling revealed large variability in oromucosal absorption of Δ9‐tetrahydrocannabinol in older patients with poor appetite

British Journal of Clinical Pharmacology, EarlyView.
Aim Cannabis‐based medicines are gaining interest and being explored for new therapeutic indications, many of which commonly affect older medical patients. As most previous studies of the population pharmacokinetics of cannabinoids have been performed in healthy adults, this study aimed to investigate the population pharmacokinetics of Δ9 ...
Ida Klitzing Storgaard, Rikke Lundsgaard Nielsen, Morten Baltzer Houlind, Olivia Bornæs, Louise Westberg Strejby Christensen, Aino Leegaard Andersen, Helle Gybel Juul‐Larsen, Lillian Mørch Jørgensen, Torben Breindahl, Baker Nawfal Jawad, Izzet Altintas, Ove Andersen, Trine Meldgaard Lund   +12 more
wiley   +1 more source

Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy

Frontiers in Neurology, 2019
Objective: Controlled and open label trials have demonstrated efficacy of cannabidiol for certain epileptic encephalopathies. However, plant derived cannabidiol products have been used almost exclusively. Efficacy of synthetically derived cannabidiol has
Kerstin A. Klotz, Kerstin A. Klotz, Daniel Grob, Martin Hirsch, Birgitta Metternich, Andreas Schulze-Bonhage, Julia Jacobs   +6 more
doaj   +1 more source

Marijuana law reform in Texas [PDF]

, 2015
textMarijuana law reform has become a significant issue across the country. Many states have passed reform of one kind or another and even President Obama has come out in favor of medical marijuana.
Winter, Bryan Alick
core   +1 more source

Cannabidiol impairs sperm quality and function in adult mice

Middle East Fertility Society Journal
Background Considering the growing therapeutic use of cannabidiol as well as the presence of cannabinoid receptors in sperm and its possible genotoxic activity, the effect of cannabidiol on sperm quality and function was examined.
Azam Govahi, Sahar Eghbali, Marziyeh Ajdary, Fatemehsadat Amjadi, Mahsa Nazari, Farzaneh Mohammadzadeh Kazorgah, Mehdi Mehdizadeh   +6 more
doaj   +1 more source

Hemp in Animal Diets—Cannabidiol

Animals, 2022
In recent years, interest in hemp use has grown owing to its chemical and medicinal properties. Several parts of this plant, such as seeds, leaves, flowers, and stems are used in medicine, industry, and environmental preservation.
Sepideh Fallahi, Łukasz Bobak, Sebastian Opaliński   +2 more
doaj   +1 more source

Interaction between Cannabinoid System and Toll-Like Receptors Controls Inflammation [PDF]

, 2016
Since the discovery of the endocannabinoid system consisting of cannabinoid receptors, endogenous ligands, and biosynthetic and metabolizing enzymes, interest has been renewed in investigating the promise of cannabinoids as therapeutic agents.
McCoy, Kathleen L.
core   +4 more sources

Expanding the Phenotype of CYFIP2‐Related Developmental Epileptic Encephalopathy: Case Report and Literature Review

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Background Pathogenic CYFIP2 variants cause developmental and epileptic encephalopathy (DEE), characterized by early‐onset intractable epilepsy and developmental delay. The disease course has not been delineated. Codon Arg87 is a de novo mutational hotspot associated with a severe DEE phenotype via gain‐of‐function mechanisms. Currently, there
Michaela Squire, Jenna K. Lea, Zheng (Jane) Fan, Senyene E. Hunter   +3 more
wiley   +1 more source

Genetic Background Can Result in a Marked or Minimal Effect of Gene Knockout (GPR55 and CB2 Receptor) in Experimental Autoimmune Encephalomyelitis Models of Multiple Sclerosis [PDF]

, 2013
PMCID ...
A Compston, A Shetty, A Zimmer, AC Howlett, AE Bygrave, C Bolton, C Delarasse, C Delarasse, C Teuscher, Carolyn Tanner, CS Wu, CS Wu, D Baker, D Baker, D Baker, D Baker, D Baker, D Baker, D Baker, D McHugh, David Baker, David L. Selwood, DL Smith-Bouvier, E de Lago, E Kozela, E Montero, E Zurita, F Docagne, F Wu, G Disanto, G Musumeci, G Paltser, G Pryce, G Pryce, G Wotherspoon, Gareth Pryce, Gavin Giovannoni, Gregory J. Michael, H Kataoka, HM Vesterinen, I Mendel, J Corey-Bloom, J Karlsson, J Palazuelos, JA Encinas, JB Davis, JH Slingsby, JK O'Neill, JL Croxford, JL Croxford, JM Coquet, JP Zajicek, K Li, K Maresz, KM Spach, L Cristino, LM Olsson, LS Whyte, M Sundvall, M Webb, MF Festing, NA Balenga, NE Buckley, O Ofek, PC Staton, PD Fillmore, PM Hoi, RA Ross, RA Ross, RC Axtell, RG Pertwee, RG Pertwee, RJ Butterfield, Roberto Furlan, RS Graves, Ruth A. Ross, S Al-Izki, S Al-Izki, S Amor, S Amor, S Amor, S Katona, S Levine, S Levine, S Rossi, S Saadoun, Samuel J. Jackson, SC Landis, SJ Allen, Sofia Sisay, V Devonshire, Y Okuda, ZY Lou   +92 more
core   +3 more sources

Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3‐Way Crossover Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox–Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti‐seizure medication (ASM).
Andriy A. Gorbenko, Catherine M.K.E. de Cuba, Annika A. de Goede, Titiaan E. Post, Roman Bohoslavsky, Pamela K. Strugala, Jules A.A.C. Heuberger, Geert Jan Groeneveld   +7 more
wiley   +1 more source

Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature. [PDF]

, 2019
Fragile X syndrome (FXS) is an X-linked dominant disorder caused by a mutation in the fragile X mental retardation 1 gene. Cannabidiol (CBD) is an exogenous phytocannabinoid with therapeutic potential for individuals with anxiety, poor sleep, and ...
Bonn-Miller, Marcel, Hagerman, Randi, Tartaglia, Nicole   +2 more
core